US Edition
Vor Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
The company said Trafigura will buy 8,000 metric tonnes a year for 10 years as project finance interest topped $1 billion.
- Standard Lithium released its 2025 financial results on Monday, March 30, 2026, reporting progress on the South West Arkansas Project and resource expansion in East Texas.
- The Arkansas Oil and Gas Commission granted unanimous approval for the company's Integration Application for the SWA Project, a key de-risking step providing certainty on the resource.
- Three major Export Credit Agencies, including Export-Import Bank of the United States and Export Finance Norway , expressed interest in providing over $1 billion in senior secured project debt for Phase 1.
- Management signed its first binding customer offtake agreement with Trafigura, committing to supply 8,000 metric tonnes of battery-quality lithium carbonate annually beginning at commercial production start.
- The company targets a Final Investment Decision in 2026 to begin construction while expanding its East Texas footprint toward an annual production goal of over 100,000 tonnes of lithium chemicals.
45 Articles
45 Articles
Solana Company Reports Fourth Quarter and Full Year 2025 Financial Results
NEWTOWN, Pa., March 30, 2026 (GLOBE NEWSWIRE) -- Solana Company (NASDAQ: HSDT) (the “Company” or “HSDT”), a publicly listed company that has expanded its business to include a digital asset treasury (“DAT”) dedicated to acquiring and holding Solana tokens (“SOL”),…
Bennington Banner
HireQuest Reports Financial Results for Fourth Quarter and Full Year 2025
GOOSE CREEK, S.C., March 30, 2026 /PRNewswire/ -- HireQuest (Nasdaq: HQI), a national franchisor of on-demand staffing and executive search services, today reported financial results for the fourth quarter and full year ended December 31, 2025.
Sangamo Therapeutics Reports Recent Business Highlights And Fourth Quarter And Full Year 2025 Financial R
Announced in June, positive topline results from registrational STAAR study in Fabry disease, including positive mean annualized estimated glomerular filtration rate (eGFR) slope at 52-weeks across all dosed patients in study, which U.S. Food and Drug Administration (FDA) reiterated in October may serve as primary basis of approval under Accelerated Approval pathway Rolling submission of Biologics License Agreement (BLA) to FDA seeking ST-920 ap…
Coverage Details
Bias Distribution
- 59% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium